You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. SMALL MOLECULE ANTAGONISTS OF PF FOR THE TREATMENT AND PREVENTION OF HIT

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NHLBI

    DESCRIPTION provided by applicant We have discovered the first ever inhibitors of PF a platelet protein central to the pathophysiology of heparin induced thrombocytopenia HIT Heparin is a naturally occurring anticoagulant that prevents the formation of clots and extension of existing clots within the vasculature and major medical applications of heparin include dialysis cardiac catheteri ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Small Molecule Inhibitors of HIV Nef Virulence Factor for Treatment of HIV AIDS

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: 100

    DESCRIPTION provided by applicant While HIV AIDS can be managed with antiretroviral drugs these agents do not clear the virus and require life long administration Recently we discovered a completely new class of compounds that interfere with the HIV virulence factor called Nef This viral protein is critical to HIV replication in vivo immune escape of HIV infected cells and AIDS progre ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Developing Intravesical Liposomes for Interstitial Cystitis

    SBC: Lipella Pharmaceuticals Inc.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Lipella Pharmaceuticals Inc. (Pittsburgh, PA) is a clinical-stage pharmaceutical company specializing in intravesical therapies for urinary bladder dysfunctions. Lipella is submitting a research proposal to the Small Business Technology Transfer program titled Developing Intravesical Liposomes for Interstitial Cystitis . The project proposes to evaluate the sa ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  4. An Early-Phase Clinical Trial Evaluating ABC294640 in Patients with Refractory/Re

    SBC: Apogee Biotechnology Corporation            Topic: 102

    DESCRIPTION provided by applicant Diffuse large B cell lymphoma DLBCL represents one of the most common variants of Non Hodgkinandapos s lymphoma NHL and oncogenic herpesviruses EBV and KSHV are the etiologic agents for the majority of these tumors in patients over or those infected with the human immunodeficiency virus HIV Despite modest improvements in outcomes for patients rece ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Developing Intravesical Liposomes for Interstitial Cystitis

    SBC: Lipella Pharmaceuticals Inc.            Topic: NIDDK

    DESCRIPTION provided by applicant Lipella Pharmaceuticals Inc Pittsburgh PA is a clinical stage pharmaceutical company specializing in intravesical therapies for urinary bladder dysfunctions Lipella is submitting a research proposal to the Small Business Technology Transfer program titled andquot Developing Intravesical Liposomes for Interstitial Cystitisandquot The project proposes to e ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  6. A Rapid assay for RNA targeted drugs: Instrumentation Supplement

    SBC: NUBAD LLC            Topic: 300

    DESCRIPTION provided by applicant Some of the most significant therapies that treat disease target nucleic acids Drugs that target nucleic acid include cancer drugs antibiotics and antivirals Combined these classes of drugs have annual sales worldwide of $ billion Antibiotics that target nucleic acids account for $ billion of the $ billion of sales annuall for all antibiotics an ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Assessing the Bite Counter as a Tool for Food Intake Monitoring: Phase II

    SBC: BITE TECHNOLOGIES, LLC            Topic: 300

    DESCRIPTION provided by applicant Self monitoring has been described as the andquot cornerstone of the behavioral treatment of obesityandquot Consistent self monitoring of energy intake is associated with improved dietary adherence and weight loss and maintenance The problem is that individuals are notoriously bad at self monitoring their intake and suffer from an underreporting bias The s ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Reversal of Myocardial Infarction by Localized Stimulation

    SBC: Micro Vide, LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Heart attacks i e myocardial infarction or MI occur in more than million patients annually Advances in pharmacological therapy have dramatically improved survival following the initial MI Consequently the number of patients with previous MI continues to increase and as a result put in jeopardy millions of patients for development of heart failure I ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government